相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Switching to a protease inhibitor-containing, nucleoside-sparing regimen (lopinavir/ritonavir plus efavirenz) increases limb fat but raises serum lipid levels - Results of a prospective randomized trial (AIDS clinical trial group 5725s)
Pablo Tebas et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2007)
Class of antiretroviral drugs and the risk of myocardial infarction
Nina Friis-Moller et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Less lipoatrophy and better lipid profile with abacavir as compared to stavudine -: 96-week results of a randomized study
Daniel Podzamczer et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2007)
Carotid intimal medial thickness in human immunodeficiency virus-infected women: Effects of protease inhibitor use, cardiac risk factors, and the metabolic syndrome
Stine Johnsen et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2006)
Incidence of metabolic syndrome in a cohort of HIV-infected adults and prevalence relative to the US population (National Health and Nutrition Examination Survey)
Denise L. Jacobson et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2006)
Pathogenesis of lipodystrophy and metabolic syndromes associated with HIV infection
Agustin Munoz-Sanz et al.
MEDICINA CLINICA (2006)
Mixed patterns of changes in central and peripheral fat following initiation of antiretroviral therapy in a randomized trial
K Mulligan et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2006)
Interpatient variability in the pharmacokinetics of the HIV non-nucleoside reverse transcriptase inhibitor efavirenz:: the effect of gender, race, and CYP2B6 polymorphism
D Burger et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2006)
Effects of discontinuing stavudine or protease inhibitor therapy on human immunodeficiency virus-related fat redistribution evaluated by dual-energy X-ray absorptiometry
N Tavassoli et al.
PHARMACOTHERAPY (2006)
Body fat and other metabolic effects of atazanavir and efavirenz, each administered in combination with zidovudine plus lamivudine, in antiretroviral-naive HIV-infected patients
JG Jemsek et al.
CLINICAL INFECTIOUS DISEASES (2006)
Cardiovascular risk in patients with HIV infection - Impact of antiretroviral therapy
Bente Magny Bergersen
DRUGS (2006)
HIV protease inhibitor-specific alterations in human adipocyte differentiation and metabolism
Roy J. Kim et al.
OBESITY (2006)
Changes in body fat measured by DEXA in patients taking different formulations of stavudine
Y Yang et al.
HIV CLINICAL TRIALS (2005)
Intracellular and plasma pharmacokinetics of efavirenz in HIV-infected individuals
LM Almond et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2005)
Redefining lipodystrophy syndrome - Risks and impact on clinical decision making
KA Lichtenstein
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2005)
Efficacy and tolerability of a nucleoside reverse transcriptase inhibitor-sparing combination of lopinavir/ritonavir and efavirenz in HIV-1-infected patients
C Allavena et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2005)
Endoplasmic reticulum stress links dyslipidemia to inhibition of proteasome activity and glucose transport by HIV protease inhibitors
RA Parker et al.
MOLECULAR PHARMACOLOGY (2005)
Simplification therapy with once-daily emtricitabine, didanosine, and efavirenz in HIV-1-infected adults with viral suppression receiving a protease inhibitor-based regimen:: A randomized trial
JM Molina et al.
JOURNAL OF INFECTIOUS DISEASES (2005)
Body composition and metabolic changes in antiretroviral-naive patients randomized to didanosine and stavudine vs. abacavir and lamivudine
JC Shlay et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2005)
Fat distribution in HIV-infected women in the United States - DEXA substudy in the Women's Interagency HIV Study
K Mulligan et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2005)
Regional body fat distribution in HIV-infected patients with lipodystrophy
WL Dinges et al.
JOURNAL OF INVESTIGATIVE MEDICINE (2005)
Reversibility of lipoatrophy in HIV-infected patients 2 years after switching from a thymidine analogue to abacavir: the MITOX Extension Study
A Martin et al.
AIDS (2004)
In vitro suppression of the lipogenic pathway by the nonnucleoside reverse transcriptase inhibitor efavirenz in 3T3 and human preadipocytes or adipocytes
K El Hadri et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
Improvement in lipoatrophy associated with highly active antiretroviral therapy in human immunodeficiency virus-infected patients switched from stavudine to abacavir or zidovudine: The results of the TARHEEL study
GA McComsey et al.
CLINICAL INFECTIOUS DISEASES (2004)
Efficacy and safety of tenofovir DF vs stavuldine in combination therapy in antiretroviral-naive patients - A 3-year randomized trial
JE Gallant et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2004)
Some HIV protease inhibitors alter lamin A/C maturation and stability, SREBP-1 nuclear localization and adipocyte differentiation
M Caron et al.
AIDS (2003)
Differential effect of HIV protease inhibitors on adipogenesis: intracellular ritonavir is not sufficient to inhibit differentiation
C Vernochet et al.
AIDS (2003)
Substitution of nevirapine, efavirenz, or abacavir for protease inhibitors in patients with human immunodeficiency virus infection
E Martinez et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Outcome of 2 simplification strategies for the treatment of human immunodeficiency virus type 1 infection
F Maggiolo et al.
CLINICAL INFECTIOUS DISEASES (2003)
Cardiovascular disease risk factors in HIV patients -: association with antiretroviral therapy.: Results from the DAD study
N Friis-Moller et al.
AIDS (2003)
Randomized, controlled, 48-week study of switching stavudine and/or protease inhibitors to combivir/abacavir to prevent or reverse lipoatrophy in HIV-infected patients
M John et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2003)
An objective case definition of lipodystrophy in HIV-infected adults: a case-control study
A Carr et al.
LANCET (2003)
Therapeutic drug monitoring of the HIV/AIDS drugs abacavir, zidovudine, efavirenz, nevirapine, indinavir, lopinavir, and nelfinavir
J Donnerer et al.
PHARMACOLOGY (2003)
HIV and antiretroviral drug distribution in plasma and fat tissue of HIV-infected patients with lipodystrophy
N Dupin et al.
AIDS (2002)
Thymidine analogue withdrawal for lipoatrophic patients on protease-sparing therapy improves lipoatrophy but compromises antiviral control: the PllLR extension study
DE Smith et al.
AIDS (2002)
Indinavir inhibits sterol-regulatory element-binding protein-1c-dependent lipoprotein lipase and fatty acid synthase gene activations
AR Miserez et al.
AIDS (2002)
Abacavir substitution for nucleoside analogs in patients with HIV lipoatrophy - A randomized trial
A Carr et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2002)
Association between altered expression of adipogenic factor SREBP1 in lipoatrophic adipose tissue from HIV-1-infected patients and abnormal adipocyte differentiation and insulin resistance
JP Bastard et al.
LANCET (2002)
Virological, immunological, and clinical impact of switching from protease inhibitors to nevirapine or to efavirenz in patients with human immunodeficiency virus infection and long-lasting viral suppression
E Negredo et al.
CLINICAL INFECTIOUS DISEASES (2002)
Switching from protease inhibitors to efavirenz: differences in efficacy and tolerance among risk groups: a case-control study from the Swiss HIV Cohort
B Hirschel et al.
AIDS (2002)
Methods of assessing body shape and composition in HIV-associated lipodystrophy
A Schwenk
CURRENT OPINION IN INFECTIOUS DISEASES (2002)
Failure to maintain long-term adherence to highly active antiretroviral therapy:: the role of lipodystrophy
S Duran et al.
AIDS (2001)
Switching to nevirapine decreases insulin levels but does not improve subcutaneous adipocyte apoptosis in patients with highly active antiretroviral therapy-associated lipodystrophy
P Domingo et al.
JOURNAL OF INFECTIOUS DISEASES (2001)
HIV protease inhibitor induces fatty acid and sterol biosynthesis in liver and adipose tissues due to the accumulation of activated sterol regulatory element-binding proteins in the nucleus
TM Riddle et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
Sterol regulatory element-binding proteins and reactive oxygen species: potential role in highly-active antiretroviral therapy (HAART)-associated lipodystrophy
PV Nerurkar et al.
CLINICAL BIOCHEMISTRY (2001)
HIV protease inhibitor substitution in patients with lipodystrophy: a randomized, controlled, open-label, multicentre study
A Carr et al.
AIDS (2001)
Clinical assessment of HIV-associated lipodystrophy in an ambulatory population
KA Lichtenstein et al.
AIDS (2001)
Risk of lipodystrophy in HIV-1-infected patients treated with protease inhibitors:: a prospective cohort study
E Martinez et al.
LANCET (2001)
Clinical pharmacokinetics of non-nucleoside reverse transcriptase inhibitors
PF Smith et al.
CLINICAL PHARMACOKINETICS (2001)
Suppression of preadipocyte differentiation and promotion of adipocyte death by HIV protease inhibitors
P Dowell et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2000)
Impact of switching from human immunodeficiency virus type 1 protease inhibitors to efavirenz in successfully treated adults with lipodystrophy
E Martínez et al.
CLINICAL INFECTIOUS DISEASES (2000)
Sonographic assessment of regional fat in HIV-1-infected people
E Martínez et al.
LANCET (2000)
HIV protease inhibitors block adipogenesis and increase lipolysis in vitro
JM Lenhard et al.
ANTIVIRAL RESEARCH (2000)
Contribution of nucleoside analogue reverse transcriptase inhibitors to subcutaneous fat wasting in patients with HIV infection
SA Mallal et al.
AIDS (2000)
The mechanism of insulin resistance caused by HIV protease inhibitor therapy
H Murata et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2000)
Stimulation of vitamin A1 acid signaling by the HIV protease inhibitor indinavir
JM Lenhard et al.
BIOCHEMICAL PHARMACOLOGY (2000)
A syndrome of lipoatrophy, lactic acidaemia and liver dysfunction associated with HIV nucleoside analogue therapy: contribution to protease inhibitor-related lipodystrophy syndrome
A Carr et al.
AIDS (2000)
HIV protease inhibitors block human preadipocyte differentiation, but not via the PPARγ/RXR heterodimer
JM Wentworth et al.
JOURNAL OF ENDOCRINOLOGY (2000)
分享论文
